Open Access

Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

  • Authors:
    • Xinjing Ding
    • Jianghua Ding
    • Zhaohui Leng
    • Yun Song
  • View Affiliations

  • Published online on: September 22, 2022     https://doi.org/10.3892/ol.2022.13520
  • Article Number: 400
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osimertinib, as the first third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally as the priority front‑line therapeutic for advanced non‑small cell lung cancer (NSCLC) carrying EGFR‑sensitive mutations. However, patients inevitably acquire drug resistance to osimertinib. Aumolertinib is the second third­‑generation EGFR‑TKI and has been similarly approved as a first‑line treatment agent. The present study reports the cases of 3 patients who were challenged with aumolertinib after osimertinib failure. All 3 patients achieved a partial remission. The progression‑free survival periods following aumolertinib were 10.0, 11 and 9.0 months (at the time of writing the study). Although the patient in case 2 succumbed to an intracerebral hemorrhage due to hypertension, aumolertinib remained effective as a treatment in cases 1 and 3. The present case series suggests the use of aumolertinib challenge as an optional treatment for patients with metastatic NSCLC harboring EGFR‑sensitive mutations after osimertinib failure. The therapeutic strategy of switching from osimertinib to aumolertinib is worth exploring further in the near future.

Related Articles

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding X, Ding J, Leng Z and Song Y: Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series. Oncol Lett 24: 400, 2022
APA
Ding, X., Ding, J., Leng, Z., & Song, Y. (2022). Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series. Oncology Letters, 24, 400. https://doi.org/10.3892/ol.2022.13520
MLA
Ding, X., Ding, J., Leng, Z., Song, Y."Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series". Oncology Letters 24.5 (2022): 400.
Chicago
Ding, X., Ding, J., Leng, Z., Song, Y."Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series". Oncology Letters 24, no. 5 (2022): 400. https://doi.org/10.3892/ol.2022.13520